Visit The Boston Globe Share on Twitter Share on Facebook Comment on this Scroll to top of page By Amy Sutherland May 16, 2018 DRAMBUIE THE GOLDEN RETRIEVER lies on his back on the floor, paws in the air, as his owner runs her hands over him. On this December night, like every night, Gina Alongi searches for sore spots and ticks, her fingers feeling for anything that might be amiss with her beloved dog. She starts with his chest and traces circles with her index and middle fingers down his torso. When she reaches the bare skin of his abdomen she pauses. She feels a small lump.It’s been eight years since Alongi flew to Ohio to buy a horse, only to come home with a new dog. Amid the thousands of quarter horses at this annual sale, one tent sold puppies. By the end of the day, there was a single one left. He looked so sad by himself. Alongi snuck him into her hotel room and then bought an additional plane ticket to fly him back to Westborough with her. Drambuie … [Read more...] about An experimental cancer treatment cured this dog. Could it work for people?
Experimental lung cancer treatments
Two new clinical trials for kidney cancer are available at Lehigh Valley Health Network through its partnership with Memorial Sloan Kettering Cancer Center, giving patients options for experimental treatment and participation in research that advances kidney cancer treatment.The immunotherapy trials test combinations of drugs that cut off blood supply to tumor cells and help the immune system find and fight cancer cells.A decade ago, late-stage kidney cancer patients had a small chance of living past a year after diagnosis, said Dr. Suresh Nair, medical director of LVHN Cancer Institute.“The amount of progress that’s happened in the year is staggering,” he said. “Kidney cancer has probably progressed the most among all the cancer areas in the past year.”On Thursday, about 30 patients made it to their second annual celebration of advancements in kidney cancer treatment. The event, which was sponsored by the Andy Derr Foundation for Kidney Cancer Research … [Read more...] about LVHN launches two clinical trials for kidney cancer
Some cancer centers are misleading the public by advertising clinical trials as a way for patients to access cutting-edge treatments, two ethics professors argue in a paper published today. Billboards like this one imply that clinical trials amount to a patient benefit, two ethicists say. Alex John London, PhD, of Carnegie Mellon University and Jonathan Kimmelman, PhD, of McGill University wrote in JAMA Oncology that “strong messages equating access to clinical trials with therapy imply that unproven drugs are already established as therapy.” They said those messages contradict the very purpose of a clinical trial, which is to determine whether a therapy works. Among the examples they cited: A billboard erected by the Georgia Cancer Center declares: “Clinical Trials: Another Reason to See Us First.” In a Johns Hopkins Medicine video, a doctor says clinical trials “open up new treatments that (his patients) otherwise would not have available to … [Read more...] about Ethicists find fault with cancer centers marketing their clinical trials as a patient benefit
(Reuters) - AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023. This is the second deal AbbVie has signed over the past year as it tries to safeguard patents on Humira, which is the world’s top-selling prescription medicine. The drug, which treats rheumatoid arthritis, raked in $18.43 billion in sales last year and accounted for nearly two-thirds of AbbVie’s net revenue. While terms of the deal were undisclosed, AbbVie said it will make no payments to Samsung Bioepis and the three companies agreed to dismiss all pending lawsuits. Even if multiple Humira biosimilars are delayed from market until 2023, this can be “more than offset” by a steeper sales decline for Humira, BMO Capital Markets analyst Alex Arfaei said. Arfaei noted this is increasingly likely given the U.S. Food and Drug … [Read more...] about AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in…
Researchers are now developing a new method of killing cancer more effectively. Their strategy "starves" tumors, depriving them of the main nutrient they require to grow and spread. Glutamine is an amino acid that is abundantly found in our bodies, especially in blood and bone tissue. Its main role is to sustain the synthesis of proteins in cells. Unfortunately, though, glutamine is also a key nutrient for many types of cancerous tumors, which tend to "consume" more of this amino acid because their cells divide more rapidly. This is why research has been investigating the possibility of blocking cancer cells' access to glutamine as a new therapeutic approach in cancer treatment. Charles Manning and several other researchers from the Vanderbilt Center for Molecular Probes at Vanderbilt University in Nashville, TN, have now managed, in a breakthrough move, to stop the growth of a cancer tumor. To do so, they used an experimental compound called V-9302 to block the uptake, or absorption, … [Read more...] about Cancer breakthrough: Novel approach can ‘starve’ tumors to death